Skip to content

Genetics and Phantom Limb Pain

Integrative Genomic Analysis In Phantom Limb Pain

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01517061
Enrollment
0
Registered
2012-01-25
Start date
2012-01-03
Completion date
2014-07-30
Last updated
2019-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Pain, Polymorphism-Genetic

Keywords

Phantom Limb Pain, Genetic Polymorphisms, Genetic Susceptibility, Amputation

Brief summary

Background: \- Many people who lose a limb feel pain in the missing limb. This feeling is called phantom limb pain. Researchers do not fully understand what causes this pain. Differences in people's genes may play a role. Comparing the genes of people with and without phantom limb pain may help researchers better understand this feeling, who is likely to develop it, and how to treat it. Objectives: \- To study whether genetic differences affect phantom limb pain. Eligibility: \- Individuals at least 18 years of age who have lost an arm or leg at least 3 months ago. Design: * Participants will be screened with a medical history and physical exam. * Participants will answer questions about how they lost the limb, and whether they feel phantom limb pain. They will also have a test to measure their sensitivity to heat and cold. * Participants will provide a blood sample for genetic testing.

Detailed description

Objectives: The proposed clinical trial will investigate the role of the human genome including genetic variations and gene expression profiles on the development of phantom limb pain (PLP). Study population: Patients will be recruited from military personnel with major limb amputations. A total of one thousand subjects with upper or lower extremity amputations of any level will be enrolled in this study. Design: Eight hundred subjects with chronic PLP (PLP patient) and 200 patients without PLP (non-PLP patient) will assess the severity of their pain symptom. Each participant will undergo a routine blood draw from which DNA and RNA will be harvested. Outcome measures: Using Affymetrix SNP 6.0 technology, which identifies up to 1 million single nucleotide polymorphisms (SNPs) and 1 million copy number variations in the human genome, the differences in genomic variations between the PLP and the non-PLP patients will be analyzed. An extreme subset of PLP patients will be tested for their quantitative sensory function and profiled gene expression and epigenetic pattern with the Affymetrix Human Exon ST 1.0 and Illumina Genome Analyzer IIx. These integrative genomic analyses using genetic variations, gene expression and epigenetic profile could explain why some amputees experience chronic PLP and some do not. By studying these responses in patient samples, we will evaluate the role of genomic factors in PLP. SNP frequencies, gene expression and epigenetic profiles between PLP and non-PLP groups will be analyzed.

Interventions

None listed

Sponsors

National Institute of Nursing Research (NINR)
Lead SponsorNIH

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: PLP GROUP: * at least 18 years of age * Single or multiple upper and/or lower limb amputation * At least three months post-amputation * Ability to follow study instructions in English * Currently present on-going PLP for at least one month and at least 3 times per week NON PLP GROUP: -same with PLP group except: --Experienced PLP less than 10 times total and/or for less than two weeks

Exclusion criteria

BOTH PLP AND NON-PLP GROUPS: * Chronic systemic disease which might affect pain sensitivity and ability to participate in this study s blood draw * Any disease (such as hemophilia) or medication regimen (such as warfarin) increasing hemorrhage that would make a blood draw dangerous or inadvisable for the subject * Known uncontrolled systemic diseases; known cancer not in remission, known on-going infection, lupus, kidney disease requiring dialysis, any other systemic disease which might affect ability to participate in this study s blood draw * Inability to provide his/her own informed consent

Design outcomes

Primary

MeasureTime frame
SNP frequency between PLP and non-PLP group

Secondary

MeasureTime frame
Gene expression profile between PLP and non-PLP group
Epigenetic profile between PLP and non-PLP group

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026